Statement of Changes in Beneficial Ownership (4)
January 19 2018 - 5:05PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Novartis Bioventures Ltd
|
2. Issuer Name
and
Ticker or Trading Symbol
Altimmune, Inc.
[
ALT
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
__
X
__ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O NOVARTIS INTERNATIONAL AG, LICHTSTRASSE 35
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/17/2018
|
(Street)
BASEL, V8 CH-4056
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock, par value $0.0001
|
1/17/2018
|
|
J
(1)
|
|
176586
|
A
|
(1)
|
2534561
|
I
|
See Footnote
(2)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Series B Convertible Preferred Stock
|
$2.67
(3)
|
1/17/2018
|
|
J
(1)
|
|
|
344.9398
|
8/21/2017
|
8/15/2018
|
Common Stock, par value $0.0001
|
129188
|
(1)
|
2069.6276
|
I
|
See Footnote
(2)
|
Explanation of Responses:
|
(1)
|
Pursuant to the terms of the Series B Convertible Preferred Stock (the "Preferred Stock"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock") at the installment conversion price of $1.6420 per share of Common Stock.
|
(2)
|
The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG.
|
(3)
|
The Issuer's Preferred Stock is convertible at any time at the option of the holder into shares of the Issuer's Common Stock, subject to certain restrictions, at an initial conversion price of $2.67 per share and a stated amount of $1,000 per share.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Novartis Bioventures Ltd
C/O NOVARTIS INTERNATIONAL AG
LICHTSTRASSE 35
BASEL, V8 CH-4056
|
|
X
|
|
|
NOVARTIS AG
C/O NOVARTIS INTERNATIONAL AG
LICHTSTRASSE 35
BASEL, V8 CH-4056
|
|
X
|
|
|
Signatures
|
/s/ Bart Dzikowski, Secretary of the Board of Novartis Bioventures Ltd
|
|
1/19/2018
|
**
Signature of Reporting Person
|
Date
|
/s/ Stephan Sandmeier, Authorized Signatory of Novartis Bioventures Ltd
|
|
1/19/2018
|
**
Signature of Reporting Person
|
Date
|
/s/ Bart Dzikowski, Authorized Signatory of Novartis AG
|
|
1/19/2018
|
**
Signature of Reporting Person
|
Date
|
/s/ Stephan Sandmeier, Authorized Signatory of Novartis AG
|
|
1/19/2018
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Sep 2023 to Sep 2024